When mycoplasma causes so many symptoms it is known as mycoplasma induced rash and mucositis (MIRM). MIRM is a rare complication of mycoplasma infection, with patients usually reporting about a week ...

Investors in Mirum Pharmaceuticals Inc (Symbol: MIRM) saw new options begin trading this week, for the May 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

There are several stocks that passed through the screen and (MIRM) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price increase over a ...

“erythema multiforme” OR “EM” OR “Mycoplasma pneumonia induced rash and mucositis” OR MIRM OR “Reactive infectious mucocutaneous eruption” OR RIME. Candidate studies including brief reports and case ...

or mycoplasma-induced rash and mucositis (MIRM), per the CDC. That doesn’t mean you will get those complications if you don’t treat walking pneumonia, though. “Untreated, the infection will ...

or mycoplasma-induced rash and mucositis (MIRM), per the CDC. That doesn’t mean you will get those complications if you don’t treat walking pneumonia, though. “Untreated, the infection will ...

MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC. MIRM's recent acquisition of Cholbam and Chenodal from Travere Therapeutics is strategically significant. I believe that ...

Mirum Pharmaceuticals (NASDAQ:MIRM) just reported results for the first quarter of 2024. Mirum Pharmaceuticals reported earnings per share of -54 cents. This was below the analyst estimate for EPS ...